Efsubaglutide alfa in adults with overweight or obesity: Protocol for a seamless, adaptive phase 2b/3 randomized, double‐blind, placebo‐controlled trial ( LIGHT 2)
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70556 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Weiping Jia und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Shanghai Jiao Tong University School of Medicine Affiliated Sixth People's Hospital, Shanghai Clinical Ce…. Hauptthemen laut MEDLINE: Obesity, Overweight, Anti-Obesity Agents. Die Arbeit nennt 13 Literaturangaben. Gefördert von: Innogen Pharmaceutical Co. Ltd..
Abstract (Originalsprache)
Aim
To describe the design and rationale of LIGHT 2, a seamless, adaptive phase 2b/3 trial evaluating the efficacy and safety of efsubaglutide alfa for chronic weight management in adults with overweight or obesity. Materials and Methods LIGHT 2 is a multicentre, randomized, double‐blind, placebo‐controlled study in which eligible participants are assigned to efsubaglutide alfa dose regimens or matched placebo. Efsubaglutide alfa is administered with a prespecified dose‐escalation scheme to target maintenance doses delivered once weekly or once every 2 weeks. The seamless, adaptive framework enables interim evaluation to support regimen selection and progression to the confirmatory phase under a single protocol with maintained blinding and centralized oversight. An independent data monitoring committee reviews interim safety and adaptive decisions per a prespecified charter.
Results
The primary efficacy endpoint is percentage change in body weight. Key secondary endpoints include categorical weight‐loss thresholds, changes in anthropometric and cardiometabolic measures, and comprehensive safety and tolerability assessments; an imaging substudy will further characterize effects on ectopic fat in a subset of participants.
Conclusions
LIGHT 2 is designed to efficiently identify and confirm an efsubaglutide alfa regimen with clinically meaningful weight‐loss efficacy and an acceptable safety profile, while generating evidence relevant to real‐world implementation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Shanghai Jiao Tong University School of Medicine Affiliated Sixth People's Hospital, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laborator…
- Innogen Pharmaceutical Technology Co., Ltd, Shanghai, China.
- Department of Endocrinology and Metabolism, Huashan Hospital, Shanghai Medical School, Fudan University, Shanghai, China.
ORCID-Profile: Weiping Jia, Qinghua Wang
Förderung
- Innogen Pharmaceutical Co. Ltd.
Zitieren
APA
Jia, W., & Wang, Q. (2026). Efsubaglutide alfa in adults with overweight or obesity: Protocol for a seamless, adaptive phase 2b/3 randomized, double‐blind, placebo‐controlled trial ( LIGHT 2). Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70556
Vancouver
Jia W, Wang Q. Efsubaglutide alfa in adults with overweight or obesity: Protocol for a seamless, adaptive phase 2b/3 randomized, double‐blind, placebo‐controlled trial ( LIGHT 2). Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70556
BibTeX
@article{Jia2026,
author = {Jia, Weiping and Wang, Qinghua},
title = {Efsubaglutide alfa in adults with overweight or obesity: Protocol for a seamless, adaptive phase 2b/3 randomized, double‐blind, placebo‐controlled trial ( LIGHT 2)},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70556}
}
EUVIMED